We evaluated the activity of the novel spiropyrimidinetrione AZD0914 (DNA gyrase inhibitor) against clinical gonococcal isolates and international reference strains (n ‫؍‬ 250), including strains with diverse multidrug resistance and extensive drug resistance. The AZD0914 MICs were substantially lower than those of most other currently or previously recommended antimicrobials. AZD0914 should be further evaluated, including in vitro selection, in vivo emergence and mechanisms of resistance, pharmacokinetics/pharmacodynamics in humans, optimal dosing, and performance, in appropriate randomized and controlled clinical trials.
G
onorrhea is a significant public health problem globally (1) . Neisseria gonorrhoeae has developed antimicrobial resistance (AMR) to all drugs previously used as first-line treatments. In the past decade, resistance to the last options for empirical first-line antimicrobial monotherapy, i.e., the extended-spectrum cephalosporins (ESCs) cefixime and ceftriaxone, has emerged (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Alarmingly, extensively drug-resistant (XDR) (3) gonococcal isolates with high-level ESC resistance were recently described (9, 13, 19) .
The World Health Organization (WHO) (20) , Centers for Disease Control and Prevention (CDC) (21) , and European Centre for Disease Prevention and Control (ECDC) (22) have published action plans aiming to control the spread of AMR gonorrhea. One of the few new antimicrobial classes incorporates a novel spiropyrimidinetrione that operates via a novel DNA gyrase/topoisomerase IV mode-of-inhibition (23) . DNA gyrase (GyrA 2 and GyrB 2 ) and topoisomerase IV (ParC 2 and ParE 2 ) are type II DNA topoisomerases, which catalyze changes in the topology of DNA and their function is vital for DNA replication, repair, and decatenation (24) (25) (26) (27) . AZD0914 ( Fig. 1) is a novel spiropyrimidinetrione that inhibits DNA biosynthesis, causing accumulations of doublestrand cleavages, that was recently shown to have potent in vitro activity against many different bacterial species (23) .
We detailed the in vitro activity of the novel spiropyrimidinetrione AZD0914 against a large geographically (global representativeness), temporally (obtained from 1991 to 2013), and genetically diverse collection of clinical gonococcal isolates and international reference strains (n ϭ 250). The quinolone resistance-determining region (QRDR) of the gyrA gene and an AZD0914 resistance-determining region of gyrB (28) were sequenced to verify the lack of cross-resistance to fluoroquinolones and AZD0914 resistance mutations, respectively.
The strains comprised 29 international gonococcal reference strains, including the 2008 WHO reference strains (29) , 100 consecutive clinical Swedish gonococcal isolates obtained in 2013, and 121 isolates selected for their resistance phenotype. The collection included all of the currently described XDR gonococcal strains (9, 13, 19) , additional isolates with in vitro and clinical ESC resistance (8-11, 13, 15, 16) , different types of ciprofloxacin resistance, and other high-level clinical resistance and multidrug resistance (MDR) to other antimicrobials previously used for treatment. The MICs of AZD0914 (AstraZeneca Pharmaceuticals LP) were determined by the agar dilution technique according to current CLSI guidelines (30) . The MICs of ceftriaxone, spectinomycin, cefixime, ampicillin, azithromycin, ciprofloxacin, and tetracycline were determined by the Etest method (AB bioMérieux), according to the manufacturer=s instructions, and mainly interpreted according to the CLSI breakpoints (Table 1) . Selected regions of gyrA and gyrB were sequenced using primers described in Table S1 in the supplemental material.
The MIC range, modal MIC, MIC 50 , and MIC 90 of AZD0914 were 0.004 to 0.25 g/ml, 0.125 g/ml, 0.125 g/ml, and 0.25 g/ml, respectively. With exception of the ESCs, the MIC 50 , modal MIC, and MIC 90 of other antimicrobials were substantially higher than those observed for AZD0914. A total of 165 (66%) of the isolates were resistant to the previously recommended fluoroquinolone ciprofloxacin, and 92 (37%) had a ciprofloxacin MIC of Ն32 g/ml (AZD0914 MIC 90 , 0.125 g/ml). For AZD0914, the highest MIC value (0.25 g/ml) was found in 31 (12%) isolates. The MIC distributions for AZD0914 and ciprofloxacin and a comparison of the MIC values of AZD0914 and ciprofloxacin are shown in Fig. S1A and S1B, respectively, in the supplemental material. No obvious cross-resistance between AZD0914 and ciprofloxacin or any other tested antimicrobial was identified (see Fig.  S1 and Table S2 in the supplemental material). The consecutive Swedish isolates appeared to mainly represent a wild-type MIC distribution for AZD0914 (data not shown), indicating a general lack of AZD0914 resistance mutations. No nonsynonymous mutations in amino acid codons 91 and 95 in GyrA QRDR, resulting in fluoroquinolone resistance, or other nonsynonymous mutations in gyrA showed any correlations with the AZD0914 MIC values (see Table S2 ). Only seven polymorphic nucleotide positions, including five synonymous substitutions and two nonsynonymous substitutions resulting in S467N and M521I alterations, were found in the examined 480-bp region of gyrB that encodes the region of GyrB that surrounds the residues shown to confer resistance to AZD0914 (28) (see Table S2 ).
AZD0914 was also previously shown to be active against a small collection of N. gonorrhoeae isolates. However, few of these isolates were MDR or displayed resistance to, e.g., the currently recommended ESCs or high-level resistance to spectinomycin or azithromycin (31), the latter included in the introduced dual-antimicrobial treatment regimens (250 to 500 mg ceftriaxone together with 1 to 2 g azithromycin) (32, 33) . The frequency of spontaneous resistance mutations to AZD0914 has also been shown to be low. Accordingly, when five gonococcal strains (four of which showed high-level resistance to ciprofloxacin) were exposed to AZD0914, no mutants could be isolated from any strain at 8ϫ MIC (limit of detection, Ͻ3.3 ϫ 10 Ϫ8 to Ͻ 2.1 ϫ 10 Ϫ9 ), and mutants could be isolated from only two strains at lower AZD0914 concentrations. These mutants showed 16-fold to 32-fold increases in the MIC of AZD0914 (MIC, 1 to 2 g/ml). Wholegenome sequencing of the mutants identified a single mutation (D429N or K450T) in the C terminus of GyrB that resulted in the increased AZD0914 MIC, which was also confirmed by transformation experiment (28) . In the present study, the region of gyrB that contained these resistance-determining amino acid residues was highly conserved, and the in vitro-selected resistance mutations, D429N and K450T, in GyrB (28) were not found. Only two amino acid alterations in GyrB, S467N and M521I, were found among the 250 isolates, and the AZD0914 MICs of the corresponding isolates were 0.125 g/ml and 0.06 g/ml, respectively, which were within the AZD0914 wild-type MIC distribution. AZD0914 has good penetration into target tissues, good bioavailability, and sufficiently high safety and tolerability margins, as indicated from initial preclinical animal toxicology studies, to support further development.
The novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, was highly active against gonococci, and the results indicated a lack of cross-resistance to other antimicrobial classes. AZD0914 should be evaluated in additional studies, including in vitro selection and the in vivo emergence and mechanisms of AZD0914 resistance. Pharmacokinetics/phar- macodynamic properties should be further studied in humans, and appropriate randomized and strictly controlled clinical trials, including patients with both genital and extragenital (especially pharyngeal) gonorrhea, should be performed while evaluating such parameters as optimal dosing, tolerability, efficacy, cost, and safety.
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